| Literature DB >> 25691606 |
Robert J Motzer1, Eric Jonasch1, Neeraj Agarwal1, Clair Beard1, Sam Bhayani1, Graeme B Bolger1, Sam S Chang1, Toni K Choueiri1, Brian A Costello1, Ithaar H Derweesh1, Shilpa Gupta1, Steven L Hancock1, Jenny J Kim1, Timothy M Kuzel1, Elaine T Lam1, Clayton Lau1, Ellis G Levine1, Daniel W Lin1, M Dror Michaelson1, Thomas Olencki1, Roberto Pili1, Elizabeth R Plimack1, Edward N Rampersaud1, Bruce G Redman1, Charles J Ryan1, Joel Sheinfeld1, Brian Shuch1, Kanishka Sircar1, Brad Somer1, Richard B Wilder1, Mary Dwyer1, Rashmi Kumar1.
Abstract
The NCCN Guidelines for Kidney Cancer provide multidisciplinary recommendations for the clinical management of patients with clear cell and non-clear cell renal carcinoma. These NCCN Guidelines Insights highlight the recent updates/changes in these guidelines, and updates include axitinib as first-line treatment option for patients with clear cell renal carcinoma, new data to support pazopanib as subsequent therapy for patients with clear cell carcinoma after first-line treatment with another tyrosine kinase inhibitor, and guidelines for follow-up of patients with renal cell carcinoma.Entities:
Mesh：
Substances：
Year: 2015 PMID： 25691606 DOI： 10.6004/jnccn.2015.0022
Source DB: PubMed Journal: J Natl Compr Canc Netw ISSN： 1540-1405 Impact factor: 11.908